CVRx Reports First Quarter 2026 Financial and Operating Results
CVRx, Inc. reported a strong start to 2026, with a 22% growth in U.S. revenue and a total revenue of $14.8 million for Q1 2026, up from $12.4 million in Q1 2025. The increase in U.S. sales was attributed to the expansion into new territories and heightened awareness of their Barostim device. Active implanting centers rose slightly to 257, while European revenue saw a minor decline of 2%. The company announced a net loss of $13.1 million for the quarter, an improvement from the previous year’s loss of $13.8 million.
MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026.